Bleomycin (Head and Neck Cancer) Analysis and Forecasts to 2020


#28372

43pages

GlobalData

$ 2000

In Stock

 

GlobalDatas pharmaceuticals report, Bleomycin (Head and Neck Cancer) Analysis and Forecasts to 2020 provides Bleomycin sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Head and Neck Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

 

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Bleomycin including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Bleomycin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Bleomycin in the US & EU5

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 Head and Neck Cancer Market 4
2.2 Epidemiology 4
2.3 Etiology 7
2.4 GlobalData Analysis and Forecasts Report Guidance 9


3 Head and Neck Cancer Disease: Market Characterization 10
3.1 Head and Neck Cancer Disease Market 10
3.2 Head and Neck Cancer Disease Market Forecasts and CAGR 10
3.3 Drivers for the Head and Neck Cancer Disease Market 11
3.3.1 High Prevalence 11
3.3.2 High Incidence 11
3.3.3 High Mortality 12
3.3.4 Low Initial Diagnosis Rate 12


4 TNM Classification of Head and Neck cancer 13


5 Bleomycin 21
5.1 Introduction 21
5.2 Mechanism of Action 21
5.3 Clinical Studies 21
5.3.1 Meta Analysis 21
5.3.2 Northern California Oncology Group randomized trial 22
5.3.3 VUMCA I Study 23
5.4 Electrochemotherapy with Bleomycin 25
5.4.1 Clinical Trial 25
5.4.2 Results 25
5.4.3 Conclusion 25
5.5 Factors impacting Sales 26
5.5.1 Head and Neck Cancer Market 26
5.5.2 Better Efficacy in Combinations 26
5.5.3 High Competition 26
5.6 Drug Evaluation 26
5.6.1 Drug Risk Benefit Score 26
5.6.2 Intensity of Competition 28
5.7 Sales forecast 28
5.7.1 Target patient Pool of Bleomycin 28
5.7.2 Dosing 29
5.7.3 Market Penetration 29
5.7.4 Annual Cost of Therapy 29
5.7.5 Sales Projections of Bleomycin 30


6 Head and Neck Cancer Market: Appendix 38
6.1 Market Definitions 38
6.2 Abbreviations 38
6.3 Research Methodology 38
6.3.1 Coverage 39
6.3.2 Secondary Research 39
6.3.3 Forecasting 39
6.3.4 Number of Patients Approved to take the Drug 40
6.3.5 Net Penetration of Drug 40
6.3.6 Net Annual Dosing 42
6.3.7 Annual Cost of Therapy 42
6.3.8 Primary Research 42
6.3.9 Expert Panels 42
6.4 Contact Us 42
6.5 Disclaimer 43
6.6 Sources 43


Table 1:Head and Neck Cancer Incidences and Mortality, 2008-2030 5
Table 2: Head and Neck Cancer, Global, Market Forecasts($bn), 20092020 10
Table 3: TNM Classification of the Oral cavity, Larynx, Oropharynx and Hypo pharyngeal Cancers 13
Table 4: TNM Classification of the Nasopharyngeal Cancer 18
Table 5: Meta analysis: VBM Regimen 22
Table 6:Drug Risk Benefit Score of Bleomycin 27
Table 7: Head and Neck Cancer, Global, Estimated Sales of Bleomycin($m), 2002-2020 31
Table 8: Head and Neck Cancer, the US, Estimated Sales of Bleomycin($m) 2002-2020 31
Table 9: Head and Neck Cancer, the UK, Estimated Sales of Bleomycin($m) 2002-2020 32
Table 10: Head and Neck Cancer, France, Estimated Sales of Bleomycin($m) 2002-2020 33
Table 11: Head and Neck Cancer, Germany, Estimated Sales of Bleomycin($m) 2002-2020 34
Table 12: Head and Neck Cancer, Italy, Estimated Sales of Bleomycin($m) 2002-2020 35
Table 13: Head and Neck Cancer, Spain, Estimated Sales of Bleomycin($m) 2002-2020 36
Table 14: Head and Neck Cancer, Japan, Estimated Sales of Bleomycin($m) 2002-2020 37


Figure 1: Top 20 Cancers based on Incidence Global, 2008 5
Figure 2: Top 20 Cancers based on Mortality Global, 2008 6
Figure 3: Difference between Percentage Distribution of Incidence and Mortality of Top 20 Cancers , 2008 6
Figure 4: Percentage Distribution of various Cancer types in HNC considering US, EU-5 and Japan incidence, 2008 7
Figure 5: Percentage Distribution of various Cancer types in HNC considering Global incidence, 2008 7
Figure 6: Per Capita Cigarette Consumption Curve, the US, 1976-2006 8
Figure 7: HNC, Global, Market Forecasts ($bn), 20092020 10
Figure 8 Head and Neck Cancer Incidence, Global, 2008-2030 11
Figure 9: Oncology Incidence, Global, 2008-2030 12
Figure 10: Broad Classification of HNC 13
Figure 11: Detailed TNM Classification of Oral Cavity Cancer 14
Figure 12: Detailed TNM Classification of Laryngeal Cancer 15
Figure 13: Detailed TNM Classification of Oropharyngeal Cancer 16
Figure 14: Detailed TNM Classification of Hypo pharyngeal Cancer 17
Figure 15: Detailed TNM Classification of Nasopharyngeal Cancer 19
Figure 16: Classification of Head and Neck Cancer 19
Figure 17: NCOG randomized trial: Local regional Complete Response 23
Figure 18: NCOG randomized trial: 2 year Local regional Complete Response 23
Figure 19: VUMCA I Study: 5 year overall survival rate 24
Figure 20: VUMCA I Study: 5 year relapse free survival rate 24
Figure 21: Results of Electro chemotherapy with Bleomycin 25
Figure 22: Efficacy Response of Bleomycin 27
Figure 23: Drug Model Diagram of Bleomycin 29
Figure 24: Head and Neck Cancer, Global Estimated Sales of Bleomycin($m) 2002-2020 30
Figure 25: Distribution of Bleomycin sales in Major Countries 30
Figure 26: Head and Neck Cancer, the US, Estimated Sales of Bleomycin($m) 2002-2020 31
Figure 27: Head and Neck Cancer, UK, Estimated Sales of Bleomycin($m) 2002-2020 32
Figure 28: Head and Neck Cancer, France, Estimated Sales of Bleomycin($m) 2002-2020 33
Figure 29: Head and Neck Cancer, Germany, Estimated Sales of Bleomycin($m) 2002-2020 34
Figure 30: Head and Neck Cancer, Italy, Estimated Sales of Bleomycin($m) 2002-2020 35
Figure 31: Head and Neck Cancer, Spain, Estimated Sales of Bleomycin($m) 2002-2020 36
Figure 32: Head and Neck Cancer, Japan, Estimated Sales of Bleomycin($m) 2002-2020 37
Figure 33: GlobalData Methodology 38
Figure 34: Drug Model Diagram 41
Figure 35: Patients Approved for the Drug 41